GDS Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.9M Buy
16,551
+8,944
+118% +$9.14M 0.94% 48
2026
Q1
$7M Buy
7,607
+6,722
+760% +$6.81M 0.42% 69
2025
Q4
$951K Buy
885
+497
+128% +$475K 0.06% 94
2025
Q3
$296K Buy
388
+32
+9% +$23.8K 0.02% 151
2025
Q2
$278K Buy
356
+13
+4% +$10.1K 0.02% 148
2025
Q1
$283K Buy
+343
New +$285K 0.02% 141
2024
Q3
– Sell
-265
Closed -$240K – 172
2024
Q2
$240K Buy
+265
New +$212K 0.03% 119

Other funds holding LLY

GDS Wealth Management's LLY Position: Q2 2026 in Review

GDS Wealth Management increased its Eli Lilly (LLY) stake by 118% in Q2 2026, buying an estimated $9.14M and bringing the position to 16,551 shares worth $19.9M. The position accounts for 0.94% of the portfolio, ranked #48.

GDS Wealth Management first reported a position in LLY in Q2 2024 and has held it in 7 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • GDS Wealth Management held 16,551 shares of Eli Lilly worth $19.9M as of Q2 2026.
  • GDS Wealth Management bought 8,944 Eli Lilly shares in Q2 2026, an estimated $9.14M.
  • Eli Lilly made up 0.94% of GDS Wealth Management's portfolio in Q2 2026, its #48 holding.
  • GDS Wealth Management first reported a position in Eli Lilly in Q2 2024 and has held it in 7 quarters since.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on GDS Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.